With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.

Shares of AbbVie Inc. ABBV inched 0.60% higher to $201.68 Tuesday, on what proved to be an all-around great trading session ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Argus has recently raised AbbVie Inc (ABBV) stock to Buy rating, as announced on November 4, 2024, according to Finviz. Earlier, on October 17, 2024, Bernstein had initiated the stock to Mkt Perform, ...

With growth catalysts in place, along with dividend payouts, AbbVie is a good medium to long-term buy. Click here to read an ...

On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $203.55 which represents a decrease of $-0.32 or -0.16% from the prior close of $203.87. The stock opened at $204.37 and touched a ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...

(RTTNews) - While reporting financial results for the third quarter on Wednesday, biopharmaceutical company AbbVie, Inc. (ABBV) raised its adjusted earnings guidance for the full-year 2024.

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma stocks. Healthcare takes the concept of 'defensive' further than almost any industry ...